Testing sacituzumab tirumotecan for triple-negative breast cancer that has spread to the brain
Original title: Sac-TMT for Active TNBC Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial in a small number of people, so it is still a test.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing a drug called sacituzumab tirumotecan in people whose triple-negative breast cancer has spread to the brain.
Who this trial is for. This trial is for people with metastatic triple-negative breast cancer who have active brain metastases, meaning the cancer has spread to the brain. It plans to include 20 participants, and everyone in it gets the same drug, sacituzumab tirumotecan, given into a vein.
Where it stands. There are no results to share. The trial has not reported any findings. People in it would keep getting the drug until the cancer grows, until side effects become too hard, until they choose to stop, or until death. What the drug does for this group is not known yet.
What this means, and what it doesn't
What it could mean: This is one place where a new drug is being tested for cancer that has spread to the brain. If this sounds like your situation, you could ask your care team about it. They can tell you whether it makes sense for you and what other options you have.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Joining one is not a guarantee that you will be helped, and it is not a promise of a cure. The trial team decides who can take part.
Source: ClinicalTrials.gov, July 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.